secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-06-04T20:05:28+00:00
Accession:  0001493152-26-027266
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shareholders approve Lipocine stock plan amendment; authorized shares raised to 1M
--------------------------------------------------------------------------------

- Shareholders approved Sixth Amended and Restated 2014 Stock Plan on June 3, 2026.
- Plan increases individual award limit from 25,000 to 100,000 shares.
- Authorized shares increased by 400,000, from 600,000 to 1,000,000 shares.
- Four directors elected to one-year terms: Dr. Mahesh V. Patel, John W. Higuchi, Dr. Jill M. Jene, Dr. Richard Dana Ono.
- Ratification of Tanner LLC as independent auditor for FY 2026 and advisory vote on executive compensation both approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226027266/0001493152-26-027266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226027266/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer